

Hear from ProQR Therapeutics: RNA Therapeutics for Patients with Cystic Fibrosis

LONDON, UNITED KINGDOM, October 16, 2017 /EINPresswire.com/ -- SMI are thrilled to welcome Dr. Noreen Roth Henig, Chief Medical Officer, ProQR Therapeutics onto the speaker panel [RNA Therapeutics 2018!](#)
www.therapeutics-rna.com/ein

ProQR is dedicated to discovering and developing RNA therapeutics for severe genetic rare diseases. Their QR-010 molecule is designed to address the most common mutation which causes cystic fibrosis. It has now demonstrated safety and clinical activity in two early clinical trials. This program integrated a creative approach to preclinical data, delivery, and clinical trial design to quickly advance this potential RNA therapeutic for a significant orphan disease population. Using a similar creative approach, ProQR have developed their second molecule, QR-110 for individuals with Leber's congenital amaurosis Type 10 into a now on-going clinical trial. Beyond that, have a pipeline of RNA therapeutics.



“

All presentations were of excellent quality, timekeeping was perfect”

GSK

In the last several years, the RNA-based therapeutic development field has made good on the promise of decades of preclinical research. There are some outstanding and creative clinical trials using RNA-based therapeutics and strong momentum to bring these RNA-based therapeutics to patients.

For the detailed interview, check out the download centre online.

"I will share the challenges and choices made in bringing these molecules to development using QR-010 as the key example as it is farthest along."

- Noreen Roth Henig

Hear more from Dr. Henig at RNA Therapeutics this February 2018, as she presents 'RNA Therapeutics for Patients with Cystic Fibrosis: QR-010 and Beyond'

For those looking to attend there is currently a £400 [early-bird](#) saving, ending October 31st

Further information is available at: www.therapeutics-rna.com/ein

SMi presents the 9th Annual Conference:

RNA Therapeutics

Date: 21st – 22nd February 2018

Location: Holiday Inn London - Kensington Forum

Website: www.therapeutics-rna.com/ein

---end---

Contact Information:

For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Pav Solanki
SMi Group
2078276048
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.